Lupin receives approval from U.S. FDA for Efinaconazole Topical Solution

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Efinaconazole Topical Solution, 10% to market a generic equivalent of Jublia® Topical Solution, 10%, of Bausch Health Americas, Inc. The product will be manufactured at Lupin's facility in Pithampur, India.

Efinaconazole Topical Solution, 10% (RLD: Jublia® Topical Solution, 10%) had estimated annual sales of USD 274 million in the U.S. ((QVIA MAT December 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 728.25 as compared to the previous close of Rs. 745.70. The total number of shares traded during the day was 45706 in over 1915 trades.

The stock hit an intraday high of Rs. 749.10 and intraday low of 723.10. The net turnover during the day was Rs. 33440424.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 ANDA USFDA EfinaconazoleTopicalSolution Jublia BauschHealthAmericas